Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H- indol-3-yl)-ethyl]-Amide as a neuroprotectant for Alzheimers Disease by Hybridization of Curcumin and Melatonin

ACS Chemical Neuroscience

Volumn 5, Issue 8, 2014, Pages 690-699

  Chojnacki, Jeremy E ^a   Liu, Kai ^a   Yan, Xing ^a   Toldo, Stefano ^b   Selden, Tyler ^a   Estrada, Martin ^c   Rodríguez Franco, María Isabel ^c   Halquist, Matthew S ^a   Ye, Dexian ^a   Zhang, Shijun ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CSIC   (Spain)

Author keywords

Alzheimer"s disease; curcumin; hybridization; melatonin; Neuroprotectants

Indexed keywords

5 (4 HYDROXYPHENYL) 3 OXO PENTANOIC ACID[2 (5 METHOXY 1H INDOL 3 YL)ETHYL]AMIDE; AMYLOID BETA PROTEIN; CURCUMIN; MELATONIN; NEUROPROTECTIVE AGENT; OLIGOMER; UNCLASSIFIED DRUG; ANTIOXIDANT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; HYBRIDIZATION; MALE; MITOCHONDRION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; SYNTHESIS; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MELATONIN; MICE; MITOCHONDRIA; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS;

EID: 84906266231     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500081s     Document Type: Article

References (43)

1. Alzheimer"s Association (2013) 2013 Alzheimer"s Disease Facts and Figures Alzheimer;s Dementia 9, 208-245
2. Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer"s disease: progress and problems on the road to therapeutics Science (New York, N.Y.) 297, 353-356
3. Kirkitadze, M. D., Bitan, G., and Teplow, D. B. (2002) Paradigm shifts in Alzheimer"s disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies J. Neurosci. Res. 69, 567-577
4. Walsh, D. M. and Selkoe, D. J. (2007) A beta oligomers-A decade of discovery J. Neurochem. 101, 1172-1184
5. Selkoe, D. J. (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav. Brain Res. 192, 106-113
6. Bush, A. I. (2008) Drug development based on the metals hypothesis of Alzheimer"s disease J. Alzheimer"s Dis. 15, 223-240
7. Zhu, X., Su, B., Wang, X., Smith, M. A., and Perry, G. (2007) Causes of oxidative stress in Alzheimer disease Cell. Mol. Life Sci. 64, 2202-2210
8. Viegas-Junior, C., Danuello, A., da Silva Bolzani, V., Barreiro, E. J., and Fraga, C. A. (2007) Molecular hybridization: a useful tool in the design of new drug prototypes Curr. Med. Chem. 14, 1829-1852
9. Tietze, L. F., Bell, H. P., and Chandrasekhar, S. (2003) Natural product hybrids as new leads for drug discovery Angew. Chem., Int. Ed. 42, 3996-4028
10. Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., and Cole, G. M. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280, 5892-5901
11. Kim, J., Lee, H. J., and Lee, K. W. (2010) Naturally occurring phytochemicals for the prevention of Alzheimer"s disease J. Neurochem. 112, 1415-1430
12. X, W. (2009) The antiapoptotic activity of melatonin in neurodegenerative diseases CNS Neurosci. Ther. 15, 345-357
13. Rosales-Corral, S. A., Acuna-Castroviejo, D., Coto-Montes, A., Boga, J. A., Manchester, L. C., Fuentes-Broto, L., Korkmaz, A., Ma, S., Tan, D. X., and Reiter, R. J. (2012) Alzheimer"s disease: pathological mechanisms and the beneficial role of melatonin J. Pineal Res. 52, 167-202
14. Frautschy, S. A. and Cole, G. M. (2010) Why pleiotropic interventions are needed for Alzheimer"s disease Mol. Neurobiol. 41, 392-409
15. Pevet, P. (2000) Melatonin and biological rhythms Biol. Signals Recept. 9, 203-212
16. Carpentieri, A., Diaz de Barboza, G., Areco, V., Peralta Lopez, M., and Tolosa de Talamoni, N. (2012) New perspectives in melatonin uses Pharmacol. Res. 65, 437-444
17. Zhou, J. N., Liu, R. Y., Kamphorst, W., Hofman, M. A., and Swaab, D. F. (2003) Early neuropathological Alzheimer"s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels J. Pineal Res. 35, 125-130
18. Hatfield, C. F., Herbert, J., van Someren, E. J., Hodges, J. R., and Hastings, M. H. (2004) Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer"s dementia Brain 127, 1061-1074
19. Rosales-Corral, S., Acuna-Castroviejo, D., Tan, D. X., Lopez-Armas, G., Cruz-Ramos, J., Munoz, R., Melnikov, V. G., Manchester, L. C., and Reiter, R. J. (2012) Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: a protective role for melatonin Oxid. Med. Cell. Longevity 2012, 843649
20. Pandi-Perumal, S. R., BaHammam, A. S., Brown, G. M., Spence, D. W., Bharti, V. K., Kaur, C., Hardeland, R., and Cardinali, D. P. (2013) Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes Neurotoxic. Res. 23, 267-300
21. Hardeland, R. (2012) Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment Aging Dis. 3, 194-225
22. Esatbeyoglu, T., Huebbe, P., Ernst, I. M., Chin, D., Wagner, A. E., and Rimbach, G. (2012) Curcumin - from molecule to biological function Angew. Chem., Int. Ed. 51, 5308-5332
23. Wong, Y.-S., Peuchmaur, M. A., Marechal, E., Botte, C., Vial, H. J., and Saidani, N. (2009) Preparation of novel polyspirane compounds for treating malaria or toxoplasmosis, 122 pp, Université Joseph Fourier, Grenoble, France.
24. Sopher, B. L., Fukuchi, K., Kavanagh, T. J., Furlong, C. E., and Martin, G. M. (1996) Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death Mol. Chem. Neuropathol. 29, 153-168
25. Lenhart, J. A., Ling, X., Gandhi, R., Guo, T. L., Gerk, P. M., Brunzell, D. H., and Zhang, S. (2010) "Clicked" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: design, synthesis, and biological characterization J. Med. Chem. 53, 6198-6209
26. Liu, K., Gandhi, R., Chen, J., and Zhang, S. (2012) Bivalent ligands targeting multiple pathological factors involved in Alzheimer"s disease ACS Med. Chem. Lett. 3, 942-946
27. McClain, D. E., Kalinich, J. F., and Ramakrishnan, N. (1995) Trolox inhibits apoptosis in irradiated MOLT-4 lymphocytes FASEB J. 9, 1345-1354
28. Aruoma, O. I., Halliwell, B., Hoey, B. M., and Butler, J. (1989) The antioxidant action of N-Acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid Free Radicals Biol. Med. 6, 593-597
29. Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., and Herzenberg, L. A. (2007) N-Acetylcysteine - a safe antidote for cysteine/glutathione deficiency Curr. Opin. Pharmacol. 7, 355-359
30. Lezoualch, F., Skutella, T., Widmann, M., and Behl, C. (1996) Melatonin prevents oxidative stress-induced cell death in hippocampal cells NeuroReport 7, 2071-2077
31. Ishimura, A., Ishige, K., Taira, T., Shimba, S., Ono, S., Ariga, H., Tezuka, M., and Ito, Y. (2008) Comparative study of hydrogen peroxide- and 4-hydroxy-2-nonenal-induced cell death in HT22 cells Neurochem. Int. 52, 776-785
32. Reale, M., Pesce, M., Priyadarshini, M., Kamal, M. A., and Patruno, A. (2012) Mitochondria as an easy target to oxidative stress events in Parkinson"s disease CNS Neurol. Disord.: Drug Targets 11, 430-438
33. Hirst, J., King, M. S., and Pryde, K. R. (2008) The production of reactive oxygen species by complex I Biochem. Soc. Trans. 36, 976-980
34. Martin, L. J. (2010) Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis IDrugs 13, 568-580
35. Nazarewicz, R. R., Dikalova, A., Bikineyeva, A., Ivanov, S., Kirilyuk, I. A., Grigorev, I. A., and Dikalov, S. I. (2013) Does scavenging of mitochondrial superoxide attenuate cancer prosurvival signaling pathways? Antioxid. Redox. Signaling 19, 344-349
36. Brookes, P. S., Yoon, Y., Robotham, J. L., Anders, M. W., and Sheu, S. S. (2004) Calcium, ATP, and ROS: a mitochondrial love-hate triangle Am. J. Physiol.: Cell. Physiol. 287, C817-833
37. Umeda, T., Maekawa, S., Kimura, T., Takashima, A., Tomiyama, T., and Mori, H. (2014) Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice Acta Neuropathol. 127, 685-698
38. De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., Chen-Dodson, E., Kinney, G. G., and Klein, W. L. (2008) Alzheimer"s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers Neurobiol. Aging 29, 1334-1347
39. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration Proc. Natl. Acad. Sci. U.S.A. 108, 5819-5824
40. Klein, W. L. (2013) Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer"s disease? J. Alzheimer"s Dis. 33 (Suppl 1) S49-65
41. Di, L., Kerns, E. H., Fan, K., McConnell, O. J., and Carter, G. T. (2003) High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 38, 223-232
42. Fernandez-Bachiller, M. I., Perez, C., Monjas, L., Rademann, J., and Rodriguez-Franco, M. I. (2012) New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer"s disease, with cholinergic, antioxidant, and beta-Amyloid-reducing properties J. Med. Chem. 55, 1303-1317
43. Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A., and LaDu, M. J. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis J. Biol. Chem. 278, 11612-11622